Supporting date for Ixekizumab in PsA with symptoms of axial involvement.
🔹Improvement in QoL (SF-36), ASDAS, BASDAI50
🔹Maintained at 52 weeks
🔹Stricter criteria (younger, ⬆️CRP) showed similar results
https://t.co/QSJLQTxLcW
#ACR21 Abst#3147
@RheumNow
Links:
Ixekizumab Efficacy in Patients with Psoriatic Arthritis Presenting with Sympto…
https://bit.ly/3qmyxMO
08-11-2021